This trial employing MGBG, vinblastine, and cisplatin in patients with advanced NSCLC produced a 10% response rate with no durable responses. This is disappointing compared to previously cited studies, although the median overall survival of 7.0 months is comparable. The relatively mild toxicity noted in this trial suggests that more aggressive use of the same combination may be feasible.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Gralla FJ, Casper ES, Kelsen DP, Braun DW, Dukeman ME, Martini N, Young CW, and Golbey RB: Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage sched- ules. Ann Int Med 1981:95, 414–420
Itri LM, Gralla RJ, Kelsen DP, Chapman RA, Casper ES, Braun DW, Howard JE, Golbey R, Heelan RT: Cisplatin, vindesine, and bleomycin (CVB) combination chemotherapy advanced non-small cell lung cancer. Cancer 51:6, 1050–1056, March 15, 1983
Woodcock TM, Allegra JC, Richman SP, Horowitz JA, Snider HL: A Phase II evaluation of vinblastine (VLB) and dimminedichloroplatin (DDP) in non-small cell cancer of the lung. Proceedings of AACR and ASCO, March 1981
Chapman R, Kelsen D, Gralla R, Itri L, Wittes R, Young C: Phase II trials of methylgloyxal bis (guanylhydrazone) (MGBG) in 3 solid tumors. Memorial Sloan-Kettering, New York, New York, (ASCO April, 1981)
About this article
Cite this article
Chapman, R., Crowley, J., Lucas, J.G. et al. Mitogauzone, cisplatin, and vinblastine in advanced non-small cell lung cancer: A Southwest Oncology Group study. Invest New Drugs 11, 91–92 (1993). https://doi.org/10.1007/BF00873920